Ideaya announces positive interim phase 1 expansion data of ide397 in mtap-deletion urothelial and lung cancer as late-breaker oral presentation at eortc-nci-aacr 2024

~33% orr by recist 1.1: 1 cr + 8 prs out of 27 evaluable heavily pre-treated (median 2-3 prior lines, ranging from 1-7) mtap-deletion uc and nsclc patients 9 of 9 responses have confirmed by recist 1.1 (5 confirmed responses out of 18 evaluable patients reported on july 8, 2024, ide397 webcast) mtap-deletion uc: 40% (4 of 10) confirmed orr and 3 pts on treatment >250 days mtap-deletion sqnsclc: ~38% (3 of 8) confirmed orr and 4 pts on treatment >200 days multiple prs with genetic co-alterations, including mtap-deletion and kras g12d mutation in nsclc, and mtap-deletion and fgfr-tacc3 fusion in uc median dot not yet reached and >6.2 months, and median ttr ~2.7 months ~81% (17 of 21) ctdna mrr, and high dcr of 93% (25 of 27 with sd or better) ae profile: no drug-related saes or discontinuations at 30 mg once-a-day expansion dose targeting expansion of phase 1/2 study of ide397 in combination with trodelvy® in mtap-deletion uc in q4 2024; patient case study of pr by recist 1.1 and rapid >95% ctdna reduction of combination will be presented at ena 2024 ide397 demonstrated deep and durable regressions in combination with prmt5 inhibitors bms-986504 and amg 193 in preclinical models south san francisco, calif. , oct. 25, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announces phase 1 expansion data for ide397 in methylthioadenosine phosphorylase (mtap)-deletion urothelial cancer (uc) and non-small cell lung cancer (nsclc) patients as a late breaker abstract (lba) oral presentation at the 36th edition of the eortc-nci-aacr symposium (ena 2024) in barcelona, spain.
NCI Ratings Summary
NCI Quant Ranking